Výsledky vyhledávání - "M. López-Vega"

Akademický článek

A Case Study of the Possible Meteorological Causes of Unexpected Fire Behavior in the Pantanal Wetland, Brazil

Autor: Flavio T. Couto, Filippe L. M. Santos, Cátia Campos, Carolina Purificação, Nuno Andrade, Juan M. López-Vega, Matthieu Lacroix

Publikováno v: Earth, Vol 5, Iss 3, Pp 548-563 (2024)

This study provides insights into large fires in the Pantanal by analyzing the atmospheric conditions that influenced the rapid fire evolution between 13 and 14 November 2023, when fire fronts spread rapidly, leading to critical situations for firefi

Externí odkaz: https://doaj.org/article/59717a97e10b423b94eb205b1283502a

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results

Autor: Edith A. Perez, J. M. López-Vega, Martin Andersson, Thierry Petit, Valerie Easton, Claudio Zamagni, Eleonora Restuccia, Julia Kamber

Publikováno v: The Oncologist

The final efficacy and safety results are reported for the VELVET Cohort 2 trial, which investigated the coinfusion of pertuzumab and trastuzumab in a single infusion bag, followed by vinorelbine.
Background. VELVET Cohort 1 demonstrated the app

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b17e535579bcc21ef9b7807d943add48
https://doi.org/10.1634/theoncologist.2017-0079

Zobrazit plný text záznamu

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

Publikováno v: Sci Rep . 2019 Dec 27;9(1):20081
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Scientific Reports
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
SCIENTIFIC REPORTS
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-FISABIO. Repositorio Institucional de Producción Científica

The debate about surgical resection of primary tumor (PT) in de novo metastatic breast cancer (MBC) patients persists. We explored this approach's outcomes in patients included in a retrospective registry, named El Álamo, of breast cancer patients d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8df95d1a5c2724658eaae2761df5ac
https://hdl.handle.net/20.500.12105/8877

Zobrazit plný text záznamu

Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer

Autor: Josep M. Martí-Climent, María José García-Velloso, Antonio Llombart, Jose Juan Illarramendi, Antonio Antón, Luis Pina, Isabel Alvarez, Jesus Garcia-Foncillas, Valentina Boni, J. M. López-Vega

Publikováno v: Cancers, Vol 13, Iss 3511, p 3511 (2021)
Cancers
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Volume 13
Issue 14

This prospective, phase II study evaluated novel biomarkers as predictors of response to bevacizumab in patients with breast cancer (BC), using serial imaging methods and gene expression analysis. Patients with primary stage II/III BC received bevaci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67c7298032a454d68847d76869511ae8
https://doi.org/10.3390/cancers13143511

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study

Publikováno v: JOURNAL OF CLINICAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Purpose Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a regimen of epirubicin and docetaxel for node-positive early BC. Patients and Methods Pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c76095a711c6aa21768eec55a00794bf
https://doi.org/10.1200/jco.2015.61.9510

Zobrazit plný text záznamu

Randomized prospective study on the influence distal block and Gamma 3 nail on the treatment of intertrochanteric fractures of femur

Autor: J.L. Rodrigo-Pérez, M.M. Morales-Suárez, M. López-Vega, E.R. Gil-Monzó, J. López-Valenciano, J. Peralta-Nieto, R.H. Salanova-Paris

Publikováno v: Revista Española de Cirugía Ortopédica y Traumatología (English Edition). 59:26-35

Objective The purpose of this study is to assess the need to lock the Gamma 3 nail (Stryker, Mahwah, New Jersey, USA) distally for intertrochanteric fractures of femur 31-A1 and 31-A2 of the AO. Materials and methods Details were recorded on a sample

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fb8bd59c31e10e1b858f3a079af3a21d
https://doi.org/10.1016/j.recote.2014.11.001

Zobrazit plný text záznamu

Abstract P2-16-10: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer

Autor: Thierry Petit, J. M. López-Vega, L. Del Mastro, E. A. Perez, Ulrich Freudensprung, R Walker, Claudio Zamagni, L Bastière-Truchot, Martin Andersson

Publikováno v: Cancer Research. 73:P2-16

Background: HER2 overexpression or amplification, occuring in ∼15-20% of breast cancers (BC), is associated with a poor prognosis. Trastuzumab (T) and pertuzumab (P) are humanized monoclonal antibodies that bind to different HER2 epitopes, inhibiti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bddce2f12d35426df909d2de5675fcac
https://doi.org/10.1158/0008-5472.sabcs13-p2-16-10

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání